title: Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines.
abstract: The kinetic mechanisms for the inhibition of pp60(c-src) tyrosine kinase (Src TK) by 4-anilinoquinazolines, an important class of chemicals as protein kinase inhibitors, were investigated. 4-Anilinoquinazolines with a bulky group at the 4'-position of the anilino group were shown to be competitive with both ATP and peptide, whereas molecules lacking such a bulky group only displayed an inhibition pattern typical of those competitive with ATP and noncompetitive with peptide. Modifications of the substituents on the carbocyclic ring did not perturb the inhibition pattern although the affinities of these modified inhibitors for Src TK were affected. Structural modeling of Src TK with inhibitor and peptide substrate bound indicated a direct atomic conflict between the bulky 4-position group and the hydroxy of the peptide tyrosyl to which the gamma-phosphate of ATP is transferred during the kinase reaction. This atomic conflict would likely prevent simultaneous binding of both inhibitor and peptide, consistent with the observed kinetic competitiveness of the inhibitor with peptide. The dual site inhibitors appeared to have both enhanced potency and selectivity for Src TK. One such inhibitor, 4-(4'-phenoxyanilino)-6,7-dimethoxyquinazoline, had a 15 nM potency against Src TK and was selective over receptor tyrosine kinases VEGFR2 by 88-fold and C-fms by 190-fold.
authors.affiliation: Department of Molecular Biochemistry, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA. gaochao.tian@astrazeneca.com
authors.forename: G
authors.initials: G
authors.lastname: Tian
authors.forename: M
authors.initials: M
authors.lastname: Cory
authors.forename: A A
authors.initials: AA
authors.lastname: Smith
authors.forename: W B
authors.initials: WB
authors.lastname: Knight
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000814:Aniline Compounds / Q000378:metabolism / Q000494:pharmacology*; D001667:Binding, Competitive; D003198:Computer Simulation; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D009842:Oligopeptides / Q000378:metabolism; D011485:Protein Binding; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D011799:Quinazolines / Q000378:metabolism / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: C097783:4-(3-bromoanilino)-6,7-diethoxyquinazoline; D000814:Aniline Compounds; D004791:Enzyme Inhibitors; D009842:Oligopeptides; D011799:Quinazolines; D011994:Recombinant Proteins; D000255:Adenosine Triphosphate; D016392:Proto-Oncogene Proteins pp60(c-src)